Page last updated: 2024-11-13

gastrin-releasing peptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Gastrin-Releasing Peptide: Neuropeptide and gut hormone that helps regulate GASTRIC ACID secretion and motor function. Once released from nerves in the antrum of the STOMACH, the neuropeptide stimulates release of GASTRIN from the GASTRIN-SECRETING CELLS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID56841900
MeSH IDM0029527

Synonyms (3)

Synonym
gastrin-releasing peptide
80043-53-4
gastrin-releasing peptide (1-27)

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" We show here that GRP combined with agents that stimulate the cAMP/PKA pathway promotes proliferation of human gliobastoma cells."( Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling.
Brunetto, AL; Farias, CB; Flores, DG; Lima, LO; Lima, RC; Meurer, L; Roesler, R; Schwartsmann, G, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" This model requires knowledge of the equilibrium concentration of the secreted growth factor, specific receptor, and bioavailability of the antibody in the tumor interstitium."( The correct dose: pharmacologically guided end point for anti-growth factor therapy.
Avis, I; Carrasquillo, J; Cuttitta, F; Daghighian, F; Ghosh, B; Larson, SM; Mulshine, JL; Reynolds, JC; Shuke, N; Walsh, T, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Through refinement of this modeling approach more context-specific dosing of agonist/antagonists could be determined which may decrease side effects associated with the drug administration."( The correct dose: pharmacologically guided end point for anti-growth factor therapy.
Avis, I; Carrasquillo, J; Cuttitta, F; Daghighian, F; Ghosh, B; Larson, SM; Mulshine, JL; Reynolds, JC; Shuke, N; Walsh, T, 1992
)
0.28
" The presence of forskolin in the incubation medium resulted in significant upward shifts of the dose-response curves for both peptides."( Effects of brain-gut related peptides on cAMP levels in myenteric ganglia of guinea-pig small intestine.
Baidan, LV; Fertel, RH; Wood, JD, 1992
)
0.28
" A dose-response relationship was observed, with maximal stimulation of phagocytic process between 10(-12)M and 10(-9)M."( Modulation of phagocytic function in murine peritoneal macrophages by bombesin, gastrin-releasing peptide and neuromedin C.
De la Fuente, M; Del Rio, M; Ferrandez, MD; Hernanz, A, 1991
)
0.28
" The BN receptor antagonist [Leu13-psi-CH2NH-Leu14]-BN (LLBN) at 1 microM was devoid of agonist activity and displaced the BN dose-response to the right, resulting in a tenfold increase in the ED50 for BN."( Modulation of inositol lipid hydrolysis in human breast cancer cells by two classes of bombesin antagonist.
Patel, KV; Schrey, MP, 1991
)
0.28
" In all cases, BBS and GRP displayed parallel dose-response curves."( Effect of porcine gastrin releasing peptide on gastric secretion and motility and the release of hormonal peptides in conscious cats.
Bernard, C; Chayvialle, JA; Collinet, M; Cuber, JC; McDonald, TJ; Mutt, V; Vagne, M,
)
0.13
" The dose-response curves showed a characteristic inverted U-shape with high doses of both GRP and bombesin being amnestic."( Effects of bombesin and gastrin-releasing peptide on memory processing.
Flood, JF; Morley, JE, 1988
)
0.27
" Dose-response curves of pGRP for amylase release and AIB uptake were found to be biphasic."( Effects of porcine gastrin-releasing peptide on amylase release, 2-deoxyglucose uptake, and alpha-aminoisobutyric acid uptake in mouse pancreatic acini.
Akanuma, Y; Iwamoto, Y; Nakamura, R, 1983
)
0.27
" The effect by this route, however, was not behaviorally specific: BBS produced equivalent inhibitions of food and water intake at every point on the dose-response curve, and produced a marked increase in grooming which dominated the behavioral display."( Effects of peripheral and central bombesin on feeding behavior of rats.
Gibbs, J; Kulkosky, PJ; Smith, GP, 1981
)
0.26
" Although both peptides inhibited intake significantly, the dose-response functions of the peptides were different."( Microstructural analysis of licking behavior following peripheral administration of bombesin or gastrin-releasing peptide.
Gibbs, J; Smith, GP; Stratford, TR, 1995
)
0.29
" For each antagonist, we determined the dose-response effects, specificity of peptide antagonism, and biological stability in serum using Indo-1AM-based flow cytometric assays."( Effects of neuropeptide analogues on calcium flux and proliferation in lung cancer cell lines.
Alford, C; Bunn, PA; Chan, D; Gera, L; Jewett, P; Mochzuki, T; Stewart, J; Tagawa, M; Tolley, R; Yanaihara, N, 1994
)
0.29
" In clones that were sensitive to growth inhibition by GRP by virtue of their expression of relatively high levels of the GRP receptor, the dose-response curve of GRP-stimulated DNA synthesis was bell shaped."( Gastrin-releasing peptide receptor signaling resulting in growth inhibition.
Feldman, RI; Fried, S; Liang, M; Mann, E; Wu, JM, 1996
)
0.29
" Results indicate that GRP at this dose improved memory only when the dosage of scopolamine was relatively low (1 mg/kg)."( Posttraining administration of gastrin-releasing peptide improves memory loss in scopolamine- and hypoxia-induced amnesic mice.
Santo-Yamada, Y; Wada, K; Yamada, K,
)
0.13
" The first aim of this study was to pharmacologically compare the dose-response curves for scratching induced by intrathecally administered bombesin-related peptides versus morphine, which is known to elicit itch in humans."( Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice.
Ko, MC; Sukhtankar, DD, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,344)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990353 (26.26)18.7374
1990's459 (34.15)18.2507
2000's251 (18.68)29.6817
2010's233 (17.34)24.3611
2020's48 (3.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (1.29%)5.53%
Reviews110 (7.90%)6.00%
Case Studies19 (1.36%)4.05%
Observational1 (0.07%)0.25%
Other1,244 (89.37%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Open-label, Multi Center PET/CT (Positron Emission Tomography/Computed Tomography) Study for Investigation of Safety, Tolerability, Biodistribution and Diagnostic Performance of the 68Ga Labeled PET Tracer BAY86-7548 Following a Single Intravenous Adminis [NCT01205321]Phase 119 participants (Actual)Interventional2010-11-30Completed
68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer [NCT03113617]Phase 244 participants (Actual)Interventional2017-04-10Completed
A Pilot Study of 68-Ga-RM2 PET/MRI in the Evaluation of Patients With Estrogen Receptor-Positive Breast Cancer [NCT03831711]Phase 1/Phase 25 participants (Actual)Interventional2019-03-19Completed
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans [NCT02624518]Phase 2/Phase 3122 participants (Actual)Interventional2015-11-16Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02624518 (3) [back to overview]Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI
NCT02624518 (3) [back to overview]Sensitivity of MRI Alone vs PET/MRI
NCT02624518 (3) [back to overview]Specificity of MR Alone vs PET/MRI
NCT03113617 (2) [back to overview]Sensitivity, Specificity, Negative and Positive Predictive Value for Detection of Regional Nodal Metastases in Comparison to Cross Sectional Imaging Performed Contemporaneously With the 68Ga-RM2 PET
NCT03113617 (2) [back to overview]Sensitivity, Specificity, Positive, and Negative Predictive Value of 68Ga-RM2 PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy
NCT03831711 (1) [back to overview]Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI

Number of Tumor Lesions Detected by 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI

Diagnostic performance of 68Ga-RM2 as a contrast imaging label will be assessed by magnetic resonance imaging (MRI) alone, or as a combined scan with positron emission tomography (PET, collectively PET/MRI). The outcome is reported as the number of tumor lesions detected with MRI alone, or with the combination PET/MRI scan, a number without dispersion. (NCT02624518)
Timeframe: 1 day

Interventionnumber of tumor lesions (Number)
MRI scanPET/MRI scan
Diagnostic (68Ga-RM2 PET/MRI)92127

[back to top]

Sensitivity of MRI Alone vs PET/MRI

Sensitivity is the ability of a test to correctly identify patients who have the prostate cancer, ie, how well 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI correctly detects patients who truly have prostate cancer. Sensitivity is defined as [TP/(TP+FN)], where TP=true-positive, and FN=false-negative. The outcome is a percentage number with 95% confidence interval (95% CI). A higher % value means a greater probability that an imaging target identified as cancerous is confirmed by histology to be cancerous, and a lower % means reduced confidence in that result. (NCT02624518)
Timeframe: 1 day

Interventionpercentage (Number)
MRI scanPET/MRI scan
Diagnostic (68Ga-RM2 PET/MRI)48.291.8

[back to top]

Specificity of MR Alone vs PET/MRI

Specificity is the ability of a test to correctly identify patients who do not have the prostate cancer, ie, how well 68Ga-RM2 MRI vs 68Ga-RM2 PET/MRI correctly detects patients who do not have prostate cancer (does not falsely return a positive result). Specificity is defined as [TN/(TN+FP)], where TN=true-negative, and FP=false-positive. The outcome is a percentage number with 95% confidence interval (95% CI). A higher % value means a greater probability that an imaging target identified as non-cancerous is confirmed by histology to be non-cancerous, and a lower % means reduced confidence in that result. (NCT02624518)
Timeframe: 1 day

Interventionpercentage of participants (Number)
MRI alonePET/MRI scan
Diagnostic (68Ga-RM2 PET/MRI)97.288.9

[back to top]

Sensitivity, Specificity, Negative and Positive Predictive Value for Detection of Regional Nodal Metastases in Comparison to Cross Sectional Imaging Performed Contemporaneously With the 68Ga-RM2 PET

True positive patient is defined as PET positive for regional nodes, pathology at prostatectomy positive for regional nodes or PET positive for regional nodes, pathology negative for regional nodes, imaging after prostatectomy demonstrates node was not removed at surgery, and follow-up biopsy or imaging demonstrates presence of nodal disease. True negative patient is defined as PET negative for regional nodes, pathology at prostatectomy negative for regional nodes. False positive patient is defined as PET positive for regional nodes, pathology at prostatectomy is negative, and imaging after prostatectomy (NCT03113617)
Timeframe: week 1 study visit following radiopharmaceutical administration, up to 2 hours to assess

Interventionpercentage of cases (Number)
SensitivitySpecificityPositive predictive valueNegative predictive value
Diagnostic (68Ga-RM2 PET/CT)22.296.266.778.1

[back to top]

Sensitivity, Specificity, Positive, and Negative Predictive Value of 68Ga-RM2 PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy

True positive patient is defined as PET positive for regional nodes, pathology at prostatectomy positive for regional nodes or PET positive for regional nodes, pathology negative for regional nodes, imaging after prostatectomy demonstrates node was not removed at surgery, and follow-up biopsy or imaging demonstrates presence of nodal disease. True negative patient is defined as PET negative for regional nodes, pathology at prostatectomy negative for regional nodes. False positive patient is defined as PET positive for regional nodes, pathology at prostatectomy is negative, and imaging after prostatectomy (NCT03113617)
Timeframe: week 1 study visit following radiopharmaceutical administration, up to 2 hours to assess

Interventionpercentage of cases (Number)
SpecificitySensitivityPositive predictive valueNegative predictive value
Diagnostic (68Ga-RM2 PET/CT)55.692.371.485.7

[back to top]

Detection of ER Positive Breast Cancer and Metastases on 68-Ga RM2 PET/MRI

Number of lesions identified on 68-Ga RM2 positron emission tomography/magnetic resonance imaging (PET/MRI). The outcome will be reported as the number of participants with successful PET based detection of estrogen receptor (ER) positive breast cancer and metastases. (NCT03831711)
Timeframe: up to 2 hours

InterventionParticipants (Count of Participants)
Breast LesionsLymph Node Lesions
Diagnostic (68-Ga RM2, PET/MRI)41

[back to top]